Pair page
AHK-Cu with Decapeptide-12
Mechanism-tag overlap and published literature for AHK-Cu and Decapeptide-12, pulled verbatim from each Kalios compound profile. Kalios is a literature reference, not a recommendation.
Mechanism overlap
Mechanism tags are verbatim labels on each compound's profile. Generic tags ("peptide", "small-molecule", "research-chemical") are excluded from this overlap view. Tags are descriptive — not an inference about combined effect.
AHK-Cu unique
copper-tripeptidehair
Shared
cosmetic-peptide
Decapeptide-12 unique
tyrosinase-inhibitor
Quick facts
AHK-Cu
RouteTopical scalp
Half-lifeNot listed
FDA statusCosmetic ingredient
WADANot listed (N/A topical)
Decapeptide-12
RouteTopical only
Half-lifeNot listed
FDA statusCosmetic ingredient
WADAN/A (topical cosmetic)
Literature table
Classified references from each compound profile. Click a column header to sort. Click a PMID to open PubMed. Findings are quoted verbatim from each profile's literature_summary; nothing here is added or interpreted.
| Year | Compound | Source | Finding |
|---|---|---|---|
| 2013 | AHK-Cu | Dhurat R, Sukesh M, Avhad G, Dandale A, Pal A, Pund P. A Randomized Evaluator Blinded Study of Effect of Microneedling in Androgenetic Alopecia: A Pilot Study. Int J Trichology. 2013;5(1):6-11. doi:10.4103/0974-7753.114700. PMID: 23960389. (Microneedling + minoxidil RCT — the pr… PMID 23960389 | human trial |
| 1998 | AHK-Cu | Lachgar S, Charveron M, Gall Y, Bonafe JL. Minoxidil upregulates the expression of vascular endothelial growth factor in human hair dermal papilla cells. Br J Dermatol. 1998;138(3):407-411. doi:10.1046/j.1365-2133.1998.02115.x. PMID: 9580790. (Clinically validated positive-contr… PMID 9580790 | human study |
| 2001 | AHK-Cu | Yano K, Brown LF, Detmar M. Control of hair growth and follicle size by VEGF-mediated angiogenesis. J Clin Invest. 2001;107(4):409-417. doi:10.1172/JCI11317. PMID: 11181640. (Transgenic VEGF overexpression increases perifollicular vascularization, accelerates hair regrowth, and… PMID 11181640 | preclinical, in vivo |
| 2007 | AHK-Cu | Pyo HK, Yoo HG, Won CH, Lee SH, Kang YJ, Eun HC, Cho KH, Kim KH. The effect of tripeptide-copper complex on human hair growth in vitro. Arch Pharm Res. 2007;30(7):834-839. doi:10.1007/BF02978833. PMID: 17703734. (The foundational AHK-Cu in-vitro / ex-vivo paper — dermal papilla… PMID 17703734 | preclinical, in vitro |
| 1988 | AHK-Cu | Maquart FX, Pickart L, Laurent M, Gillery P, Monboisse JC, Borel JP. Stimulation of collagen synthesis in fibroblast cultures by the tripeptide-copper complex glycyl-L-histidyl-L-lysine-Cu2+. FEBS Lett. 1988;238(2):343-346. doi:10.1016/0014-5793(88)80509-x. PMID: 3169264. (Found… PMID 3169264 | preclinical, in vitro |
| 2018 | AHK-Cu | Pickart L, Margolina A. Regenerative and Protective Actions of the GHK-Cu Peptide in the Light of the New Gene Data. Int J Mol Sci. 2018;19(7):1987. doi:10.3390/ijms19071987. PMID: 29986520. (Comprehensive review of copper-peptide gene-expression effects — scaffold for AHK-Cu me… PMID 29986520 | review |
| 2008 | AHK-Cu | Pickart L. The human tri-peptide GHK and tissue remodeling. J Biomater Sci Polym Ed. 2008;19(8):969-988. doi:10.1163/156856208784909435. PMID: 18644225. (Authoritative Pickart review of the copper-peptide tissue-remodeling framework.) PMID 18644225 | review |
| 2015 | AHK-Cu | Pickart L, Vasquez-Soltero JM, Margolina A. GHK Peptide as a Natural Modulator of Multiple Cellular Pathways in Skin Regeneration. Biomed Res Int. 2015;2015:648108. doi:10.1155/2015/648108. PMID: 26236730. (Multi-pathway copper-peptide mechanism review — foundational context for… PMID 26236730 | research article |
| 2012 | AHK-Cu | Li W, Man XY, Li CM, Chen JQ, Zhou J, Cai SQ, Lu ZF, Zheng M. VEGF induces proliferation of human hair follicle dermal papilla cells through VEGFR-2-mediated activation of ERK. Exp Cell Res. 2012;318(14):1633-1640. doi:10.1016/j.yexcr.2012.05.003. PMID: 22659165. (Downstream VEG… PMID 22659165 | research article |
| 2012 | AHK-Cu | Pickart L, Vasquez-Soltero JM, Margolina A. The human tripeptide GHK-Cu in prevention of oxidative stress and degenerative conditions of aging: implications for cognitive health. Oxid Med Cell Longev. 2012;2012:324832. doi:10.1155/2012/324832. PMID: 22666519. (Copper-peptide agi… PMID 22666519 | research article |
| 2000 | AHK-Cu | Siméon A, Wegrowski Y, Bontemps Y, Maquart FX. Expression of glycosaminoglycans and small proteoglycans in wounds: modulation by the tripeptide-copper complex glycyl-L-histidyl-L-lysine-Cu(2+). J Invest Dermatol. 2000;115(6):962-968. doi:10.1046/j.1523-1747.2000.00166.x. PMID: 1… PMID 11121126 | research article |
| 1999 | AHK-Cu | Simeon A, Monier F, Emonard H, Gillery P, Birembaut P, Hornebeck W, Maquart FX. Expression and activation of matrix metalloproteinases in wounds: modulation by the tripeptide-copper complex glycyl-L-histidyl-L-lysine-Cu(2+). J Invest Dermatol. 1999;112(6):957-964. doi:10.1046/j.… PMID 10383745 | research article |
| 2018 | Decapeptide-12 | Jiang L, Hino PD, Bhatia A, Stephens TJ, Jimenez F. Efficacy of Trifecting Night Cream, a novel triple-acting skin brightening product: a double-blind, placebo-controlled clinical study. J Clin Aesthet Dermatol. 2018;11(12):25-30. (Envy Medical triple-action cream containing dec… | human trial |
| 2009 | Decapeptide-12 | Hantash BM, Jimenez F. A split-face, double-blind, randomized and placebo-controlled pilot evaluation of a novel oligopeptide for the treatment of recalcitrant melasma. J Drugs Dermatol. 2009;8(8):732-735. PMID: 19663110. (Pivotal split-face RCT pilot in five Fitzpatrick IV fema… PMID 19663110 | human trial |
| 2013 | Decapeptide-12 | Ramírez SP, Carvajal AC, Salazar JC, Arroyave G, Flórez AM, Echeverry HF. Open-label evaluation of a novel skin brightening system containing 0.01% decapeptide-12 in combination with 20% buffered glycolic acid for the treatment of mild to moderate facial melasma. J Drugs Dermato… PMID 23839199 | human pilot |
| 2012 | Decapeptide-12 | Hantash BM, Jimenez F. Treatment of mild to moderate facial melasma with the Lumixyl topical brightening system. J Drugs Dermatol. 2012;11(5):660-662. PMID: 22527440. (Open-label evaluation of the full Lumixyl brightening system in mild-to-moderate facial melasma.) PMID 22527440 | human pilot |
| 2012 | Decapeptide-12 | Open-label evaluation of the skin-brightening efficacy of a skin-brightening system using decapeptide-12 (24-week photodamage study). J Drugs Dermatol. 2012. PMID: 22401652. (24-week open-label in photodamaged facial hyperpigmentation; subset-shift improvements in grade-4 severe… PMID 22401652 | human pilot |
| 2012 | Decapeptide-12 | Ball Arefiev KL, Hantash BM. Advances in the treatment of melasma: a review of the recent literature. Dermatol Surg. 2012;38(7 Pt 1):971-984. PMID: 22583339. (Hantash-co-authored contemporary melasma-therapeutics review that situates decapeptide-12 within the broader depigmentin… PMID 22583339 | human study |
| 2019 | Decapeptide-12 | Hantash BM, Abu Ubeid A. Tyrosinase inhibitors with potent anti-senescence activity in human neonatal keratinocyte progenitors. 2019. (Extends decapeptide-12 mechanistic claims into SIRT-pathway anti-senescence in human keratinocytes — supports "brightening plus anti-aging" posi… | preclinical, in vitro |
| 2009 | Decapeptide-12 | Abu Ubeid A, Zhao L, Wang Y, Hantash BM. Short-sequence oligopeptides with inhibitory activity against mushroom and human tyrosinase. J Invest Dermatol. 2009;129(9):2242-2249. PMID: 19440221. (Foundational discovery paper — phage-display biopanning that identified decapeptide-12… PMID 19440221 | preclinical, in vitro |
| 1993 | Decapeptide-12 | Iozumi K, Hoganson GE, Pennella R, Everett MA, Fuller BB. Role of tyrosinase as the determinant of pigmentation in cultured human melanocytes. J Invest Dermatol. 1993;100(6):806-811. (Classic determinant-of-pigmentation paper establishing tyrosinase as the rate-limiting enzyme o… | preclinical, in vitro |
| 2016 | Decapeptide-12 | Ochiai A, Tanaka S, Tanaka T, Taniguchi M. New tyrosinase inhibitory decapeptide: molecular insights into the role of tyrosine residues. J Biosci Bioeng. 2016;121(6):607-613. (Independent decapeptide-class tyrosinase-inhibitor work highlighting the role of tyrosine residues in t… | mechanism / discovery |
| 2012 | Decapeptide-12 | Ubeid AA, Do S, Nye C, Hantash BM. Potent low toxicity inhibition of human melanogenesis by novel indole-containing octapeptides. Biochim Biophys Acta. 2012;1820(10):1481-1489. (Extended structure-activity work from the Hantash group on the peptide-tyrosinase inhibitor scaffold.) | mechanism / discovery |
| 2014 | Decapeptide-12 | Ubeid AA, Hantash BM. Minireview: Peptide analogs and short sequence oligopeptides as modulators of skin pigmentation. Curr Top Med Chem. 2014;14(12):1418-1424. PMID: 24894693. (Review of tyrosinase-inhibitor oligopeptides and α-MSH analogs in cosmetic and dermatologic pigment m… PMID 24894693 | review |
Related pair pages
More research context
Frequently asked
Have AHK-Cu and Decapeptide-12 been studied together?
No co-administration studies between AHK-Cu and Decapeptide-12 are catalogued on Kalios. The pair page lists only the individual published literature for each compound and any shared mechanism tags.
What mechanisms do AHK-Cu and Decapeptide-12 share?
AHK-Cu and Decapeptide-12 share these mechanism tags on their Kalios profiles: cosmetic-peptide. Tags are descriptive and verbatim from each compound profile — not an inference of combined effect.
What is the FDA status of AHK-Cu and Decapeptide-12?
AHK-Cu: Cosmetic ingredient. Decapeptide-12: Cosmetic ingredient. FDA-status text is pulled verbatim from each compound profile. See /fda-pcac-2026.html for the broader FDA Pharmacy Compounding Advisory Committee context.
Where can I find the full research on AHK-Cu and Decapeptide-12?
Full citation lists, dosing tables from the literature, reconstitution data, and the FDA / WADA status are on the individual compound profiles: the AHK-Cu profile and the Decapeptide-12 profile. The Kalios Stack Research Tool hub lists every compound covered.
Last updated: April 2026